PURPOSE: We investigated the influence of potential pre-treatment clinical prognostic factors in stage IV non-small cell lung cancer (NSCLC). METHODS AND PATIENTS: A total of 285 patients were enrolled in two consecutive prospective randomised studies which compared (study 1) carboplatin and prolonged oral etoposide (group 1; n=58) with the same etoposide alone (group 2; n=59), and (study 2) carboplatin and prolonged oral etoposide (group 1; n=84) with the same carboplatin and high-dose intravenous etoposide (group 2; n=84). RESULTS: The median survival time for all 285 patients was 7 months, while 1- and 2-year survival rates were 29% and 8%, respectively. Age did not impact on outcome ( P=0.21), while female patients did significantly better than male patients ( P<0.0001). Patients with KPS 80-100 did significantly better than those with KPS 50-70 ( P<0.0001), as did patients with less pronounced weight loss ( P<0.0001) and those with only one metastatic site when compared to those having at least two metastatic sites ( P<0.0001). When evaluated regarding the metastatic site, only subcutaneous metastatic site did not influence survival. This was confirmed within univariate analyses, but when multivariate analyses were done gender, KPS, weight loss, number of metastatic sites, presence of liver metastases and presence of brain metastases independently influenced survival, while age and other metastatic locations did not. CONCLUSION: In this analysis, gender, KPS, weight loss, number of metastatic sites, presence of liver metastases and presence of brain metastases independently influenced survival in patients with stage IV NSCLC treated with CHT.
RCT Entities:
PURPOSE: We investigated the influence of potential pre-treatment clinical prognostic factors in stage IV non-small cell lung cancer (NSCLC). METHODS AND PATIENTS: A total of 285 patients were enrolled in two consecutive prospective randomised studies which compared (study 1) carboplatin and prolonged oral etoposide (group 1; n=58) with the same etoposide alone (group 2; n=59), and (study 2) carboplatin and prolonged oral etoposide (group 1; n=84) with the same carboplatin and high-dose intravenous etoposide (group 2; n=84). RESULTS: The median survival time for all 285 patients was 7 months, while 1- and 2-year survival rates were 29% and 8%, respectively. Age did not impact on outcome ( P=0.21), while female patients did significantly better than male patients ( P<0.0001). Patients with KPS 80-100 did significantly better than those with KPS 50-70 ( P<0.0001), as did patients with less pronounced weight loss ( P<0.0001) and those with only one metastatic site when compared to those having at least two metastatic sites ( P<0.0001). When evaluated regarding the metastatic site, only subcutaneous metastatic site did not influence survival. This was confirmed within univariate analyses, but when multivariate analyses were done gender, KPS, weight loss, number of metastatic sites, presence of liver metastases and presence of brain metastases independently influenced survival, while age and other metastatic locations did not. CONCLUSION: In this analysis, gender, KPS, weight loss, number of metastatic sites, presence of liver metastases and presence of brain metastases independently influenced survival in patients with stage IV NSCLC treated with CHT.
Authors: M Sakurai; T Shinkai; K Eguchi; Y Sasaki; T Tamura; K Miura; Y Fujiwara; A Otsu; N Horiuchi; H Nakano Journal: J Cancer Res Clin Oncol Date: 1987 Impact factor: 4.553
Authors: K Kelly; J Crowley; P A Bunn; C A Presant; P K Grevstad; C M Moinpour; S D Ramsey; A J Wozniak; G R Weiss; D F Moore; V K Israel; R B Livingston; D R Gandara Journal: J Clin Oncol Date: 2001-07-01 Impact factor: 44.544
Authors: T P Miller; T T Chen; C A Coltman; R M O'Bryan; R B Vance; G B Weiss; W S Fletcher; R L Stephens; R B Livingston Journal: J Clin Oncol Date: 1986-04 Impact factor: 44.544
Authors: J P O'Connell; M G Kris; R J Gralla; S Groshen; A Trust; J J Fiore; D P Kelsen; R T Heelan; R B Golbey Journal: J Clin Oncol Date: 1986-11 Impact factor: 44.544
Authors: P J Souquet; F Chauvin; J P Boissel; R Cellerino; Y Cormier; P A Ganz; S Kaasa; J L Pater; E Quoix; E Rapp Journal: Lancet Date: 1993-07-03 Impact factor: 79.321
Authors: T Shinkai; K Eguchi; Y Sasaki; T Tamura; Y Ohe; A Kojima; F Oshita; T Miya; H Okamoto; K Iemura Journal: Cancer Chemother Pharmacol Date: 1992 Impact factor: 3.333
Authors: A J Wozniak; J J Crowley; S P Balcerzak; G R Weiss; C H Spiridonidis; L H Baker; K S Albain; K Kelly; S A Taylor; D R Gandara; R B Livingston Journal: J Clin Oncol Date: 1998-07 Impact factor: 44.544
Authors: Dong Soo Lee; Kyung Ran Park; Seung Joon Kim; Mi Joo Chung; Yun Hee Lee; Ji Hyun Chang; Jin Hyoung Kang; Sook Hee Hong; Myung Sin Kim; Yeon Sil Kim Journal: Tumour Biol Date: 2015-08-04
Authors: Lee W Jones; Whitney E Hornsby; Amy Goetzinger; Lindsay M Forbes; Emily L Sherrard; Morten Quist; Amy T Lane; Miranda West; Neil D Eves; Margaret Gradison; April Coan; James E Herndon; Amy P Abernethy Journal: Lung Cancer Date: 2011-11-22 Impact factor: 5.705
Authors: Rong Stephanie Huang; Emily O Kistner; Wasim K Bleibel; Sunita J Shukla; M Eileen Dolan Journal: Mol Cancer Ther Date: 2007-01 Impact factor: 6.261
Authors: Sonali Rudra; Amol K Narang; Timothy M Pawlik; Hao Wang; Elizabeth M Jaffee; Lei Zheng; Dung T Le; David Cosgrove; Ralph H Hruban; Elliot K Fishman; Richard Tuli; Daniel A Laheru; Christopher L Wolfgang; Luis A Diaz; Joseph M Herman Journal: Pract Radiat Oncol Date: 2012
Authors: C Tibaldi; E Vasile; I Bernardini; C Orlandini; M Andreuccetti; A Falcone Journal: J Cancer Res Clin Oncol Date: 2008-03-18 Impact factor: 4.553
Authors: Glenwood Goss; David Ferry; Rafal Wierzbicki; Scott A Laurie; Joyce Thompson; Bonne Biesma; Fred R Hirsch; Marileila Varella-Garcia; Emma Duffield; Ozlem U Ataman; Marc Zarenda; Alison A Armour Journal: J Clin Oncol Date: 2009-03-16 Impact factor: 44.544
Authors: Aminah Jatoi; James R Jett; Jeff Sloan; Paul Novotny; Joyce Ford; Uma Prabhakar; Charles L Loprinzi Journal: Support Care Cancer Date: 2004-09-15 Impact factor: 3.603